The reversible P2Y12 inhibitor ticagrelor inhibits metastasis and improves survival in mouse models of cancer.

@article{Gebremeskel2015TheRP,
  title={The reversible P2Y12 inhibitor ticagrelor inhibits metastasis and improves survival in mouse models of cancer.},
  author={Simon Gebremeskel and Terry L Levatte and Robert Stefan Liwski and Brent Johnston and Michael Bezuhly},
  journal={International journal of cancer},
  year={2015},
  volume={136 1},
  pages={234-40}
}
Tumor cells use activated platelets to promote their proliferation and metastatic potential. Because platelet activation is largely mediated through ADP engagement of purinergic P2Y12 receptors on platelets, we investigated the potential of the reversible P2Y12 inhibitor ticagrelor, a clinical agent used in the prevention of cardiovascular and cerebrovascular events, to inhibit tumor adhesion and metastasis. In B16-F10 melanoma intravenous and intrasplenic metastasis models, mice treated with a… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 23 extracted citations

Similar Papers

Loading similar papers…